Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity
about
Activated protein C: A regulator of human skin epidermal keratinocyte functionBlood-brain barrier integrity and glial support: mechanisms that can be targeted for novel therapeutic approaches in strokeProtein C anticoagulant and cytoprotective pathwaysCytoprotective-selective activated protein C therapy for ischaemic strokeProtein S protects neurons from excitotoxic injury by activating the TAM receptor Tyro3-phosphatidylinositol 3-kinase-Akt pathway through its sex hormone-binding globulin-like regionPhase 1 safety, tolerability and pharmacokinetics of 3K3A-APC in healthy adult volunteersActivated protein C analog with reduced anticoagulant activity improves functional recovery and reduces bleeding risk following controlled cortical impactThrombin mutant W215A/E217A treatment improves neurological outcome and reduces cerebral infarct size in a mouse model of ischemic stroke.The thrombomodulin analog Solulin promotes reperfusion and reduces infarct volume in a thrombotic stroke model.Protein S blocks the extrinsic apoptotic cascade in tissue plasminogen activator/N-methyl D-aspartate-treated neurons via Tyro3-Akt-FKHRL1 signaling pathway.The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A.Activated protein C protects against myocardial ischemic/reperfusion injury through AMP-activated protein kinase signaling.Purification of protein C from canine plasma.Protective effects of non-anticoagulant activated protein C variant (D36A/L38D/A39V) in a murine model of ischaemic stroke.Hereditary protein S deficiency leads to ischemic strokeProtease-activated receptor-1 cleaved at R46 mediates cytoprotective effects.An activated protein C analog with reduced anticoagulant activity extends the therapeutic window of tissue plasminogen activator for ischemic stroke in rodents.Protease-Activated Receptor-1 Supports Locomotor Recovery by Biased Agonist Activated Protein C after Contusive Spinal Cord Injury.Preclinical safety and pharmacokinetic profile of 3K3A-APC, a novel, modified activated protein C for ischemic strokeCytoprotective protein C pathways and implications for stroke and neurological disordersActivated protein C promotes neuroprotection: mechanisms and translation to the clinic.An activated protein C analog stimulates neuronal production by human neural progenitor cells via a PAR1-PAR3-S1PR1-Akt pathway.Activated protein C analog promotes neurogenesis and improves neurological outcome after focal ischemic stroke in mice via protease activated receptor 1Activated protein C analog protects from ischemic stroke and extends the therapeutic window of tissue-type plasminogen activator in aged female mice and hypertensive rats.Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research.2016 Scientific Sessions Sol Sherry Distinguished Lecturer in Thrombosis: Thrombotic Stroke: Neuroprotective Therapy by Recombinant-Activated Protein C.Activated protein C inhibits neutrophil extracellular trap formation in vitro and activation in vivo.Deficiency of Factor VII activating protease alters the outcome of ischemic stroke in mice.Cytoprotective signaling by activated protein C requires protease-activated receptor-3 in podocytes.Influence of the 3K3A-activated protein C variant on the plasma clot lysis activity of t-PA and of t-PA on the variant's anticoagulant activity.Neurotoxicity of the anticoagulant-selective E149A-activated protein C variant after focal ischemic stroke in mice.Novel association of a PROC variant with ischemic stroke in a Chinese Han population.Can adjunctive therapies augment the efficacy of endovascular thrombolysis? A potential role for activated protein C.Thrombomodulin-dependent protein C activation is required for mitochondrial function and myelination in the central nervous system.Effects of activated protein C on the size of modeled ischemic focus and morphometric parameters of neurons and neuroglia in its perifocal zone.PAR1 Biased Signaling is Required for Activated Protein C In Vivo Benefits in Sepsis and Stroke.Pericyte degeneration causes white matter dysfunction in the mouse central nervous system.
P2860
Q26830499-5DD89574-CDCC-4486-A4FF-2AC16136B09AQ26864317-32954BBD-B8B5-40E6-ADCE-43C2C39113E7Q26999113-58CB997E-342E-433D-B26A-B33EBDD10B0FQ27009122-74DB0EC4-B647-4A4F-B375-FEB47D4830CBQ28592005-DC731E12-37CB-4E0C-867E-3A9267715484Q33693490-FC82BDA4-C028-4314-B52D-491E88AC6A49Q33798916-E4994774-9C7E-492F-B73D-051310BBFC54Q33879440-8B8B5009-7C95-4722-9514-9509CE262E4EQ33924274-63EFBD9A-389A-43EE-9B88-A70E8D9CE872Q34589575-E78B3E71-8DE8-49A3-BEAE-C533901ABF92Q35067408-E71FAAE2-29B9-44A1-9CE6-14764A948DDEQ35085721-19D3D1C9-A007-40EA-AE36-CEBB8226B1A1Q35344705-5FB08A69-3681-4407-A8CC-FCB75719E3F2Q35591917-12CCABB8-A16C-4460-AB13-E8D991155F2DQ35919730-9E7EA127-43E9-4381-A067-3AEC5289907FQ36166264-00EC0C9F-DDFE-4E74-AAC9-D3BE7567E471Q36195195-90656576-6D6D-4411-9120-F9101D067F3AQ36259819-0A2587A1-A785-410E-B16E-C8FAC6C39B92Q36319554-A12805F2-1D7E-47AF-9285-C9CB3A35A987Q36379329-DCFD1C5D-4466-4C3F-BBD5-09F8AD3CDA94Q36997361-BB002F88-FA75-4F02-B29D-B77F833403E9Q37000469-79B3D15C-4AB0-4A0B-9070-00DA93E84397Q37085780-08F4985B-B68B-473D-839D-F02E6FD6D4BAQ37552150-B68BA0AE-6455-4028-A46A-B110049D38FCQ37670794-32B0D777-70C3-44AF-9080-9035DB1EE339Q38985138-47F69748-A93E-4B90-A9DD-35BF24424750Q40251372-2157AC77-6DF0-4412-88E2-FD716ADEB472Q41536355-89E4B9C3-2A71-4268-A3E5-96EFB9DAD3FCQ41773964-9C8CDE8F-1F03-4584-9B15-37EAC38172A8Q42246927-67EA5E8B-3F22-4A59-9FE1-4AAF83487BA0Q42929508-A8C9B36D-531A-4BE4-B50F-EFF383246EE6Q44137280-E381AF8F-29C0-404C-8731-D7E1102A3115Q46037752-1B6342AF-A272-4C53-A38F-98EBA724DE9FQ46475919-1229E8EC-494D-43CE-8EB3-AF25FED7D0D1Q47443410-AB1B758C-BB05-4607-B975-20BFC4496CECQ47855675-5236CF94-9C3E-4DB1-8FB4-346009596EEBQ48106116-903827A8-5301-44D8-A9CC-B607BEB538D8
P2860
Neuroprotective activities of activated protein C mutant with reduced anticoagulant activity
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Neuroprotective activities of ...... reduced anticoagulant activity
@en
Neuroprotective activities of ...... educed anticoagulant activity.
@nl
type
label
Neuroprotective activities of ...... reduced anticoagulant activity
@en
Neuroprotective activities of ...... educed anticoagulant activity.
@nl
prefLabel
Neuroprotective activities of ...... reduced anticoagulant activity
@en
Neuroprotective activities of ...... educed anticoagulant activity.
@nl
P2093
P2860
P1476
Neuroprotective activities of ...... reduced anticoagulant activity
@en
P2093
Berislav V Zlokovic
Itender Singh
John H Griffin
José A Fernández
Nienwen Chow
Rashid Deane
Theresa Barrett
Yaoming Wang
P2860
P304
P356
10.1111/J.1460-9568.2009.06664.X
P407
P577
2009-03-01T00:00:00Z